Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield SC step-therapy Prior Auths…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - South CarolinaPolicy N/A

    ACTINIC KERATOSIS - SCORE (Step Therapy Criteria)

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - South Carolina policy alerts

    Know when Blue Cross Blue Shield - South Carolina releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document lists step therapy requirements and affected products for several drug classes and specific medications for Blue Cross Blue Shield - South Carolina members. It governs prior authorization/step edits for drugs such as diclofenac gel, various antidepressants, atypical antipsychotics, Invega Hafyera, Relistor, and Rytary.

    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyACTINIC KERATOSIS - SCORE (Step Therapy Criteria)
    Policy CodePolicy N/A
    Change TypeAdministrative — no material changes
    Effective DateMar 1, 2026
    Last ReviewFeb 2, 2026
    Next Review DateFeb 2, 2026
    Key ActionDocument and confirm prior trials of specified generic alternatives before requesting approval (e.g., trial of topical fluorouracil or imiquimod for diclofenac; two generic antidepressants for listed antidepressants).
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    8products listed with step criteria
    1actinic keratosis product count
    multiplestep requirements instances
    present

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    document index

    Coverage Criteria

    Diclofenac (Actinic keratosis) Initial Therapy

    Diclofenac Sodium GEL 3% is covered when ALL of the following are met

    Diclofenac step: Trial of either topical fluorouracil OR topical imiquimod1 trial of either agent

    from chunk 3

    Antidepressants Initial Therapy

    Listed antidepressant products are covered when ALL of the following are met

    Antidepressant step: Trial of two generics from the specified list (bupropion, mirtazapine, citalopram (tablet or solution), desvenlafaxine succinate ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine hydrochloride)2 trials from list

    approve continuation of prior therapy

    Atypical Antipsychotics Initial Therapy

    Fanapt and related atypical antipsychotic products are covered when ALL of the following are met

    Atypical antipsychotic step: Trial of two oral generic formulary atypical antipsychotics from the list (asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone)2 trials from list

    approve continuation of prior therapy

    Invega Hafyera Initial Therapy

    Invega Hafyera is covered when ALL of the following are met for new starts

    Invega Hafyera step: Trial of Invega Sustenna OR Invega Trinza for new starts1 trial of either agent

    approve continuation of prior therapy; step applies to new starts only

    Relistor Initial Therapy

    Relistor is covered when ALL of the following are met

    Relistor step: Trial of lubiprostone, Constulose, Enulose, Generlac, OR lactulose1 trial of one listed agent

    from chunk 16

    Rytary Initial Therapy

    Rytary is covered when ALL of the following are met

    Rytary step: Trial of one generic carbidopa/levodopa containing formulation1 trial

    from chunk 19

    Initial Step Therapy Criteria

    Covered when ALL of the following are met for each product

    Rytary initial requirement: Trial of one generic carbidopa/levodopa containing formulation

    from chunk 19

    Zonisade initial requirement: Trial of generic zonisamide capsule; step applies to new starts only

    approve continuation of prior therapy per chunk 22

    This section contains the coverage criteria applicable to the products listed in the policy. No explicit exclusions are specified in this portion of the document; coverage is governed by the individual step-therapy and prior‑authorization requirements described for each product (for example, the Diclofenac Sodium GEL 3% requirement listed below).

    Initial Therapy Criteria (Step Therapy)

    inv-38: Diclofenac initial therapy

    Diclofenac Sodium GEL 3% is covered when ALL of the following are met

    Initial trial: Trial of topical fluorouracil OR topical imiquimod1 trial of either

    from chunk 3

    inv-39: Antidepressant initial therapy

    Listed antidepressant products are covered when ALL of the following are met

    Initial trials: Trial of two generics from enumerated antidepressant list (bupropion; mirtazapine; citalopram tablet or solution; desvenlafaxine succinate ER; duloxetine; escitalopram; fluoxetine; fluvoxamine; paroxetine; sertraline; venlafaxine HCl)2 trials

    approve continuation of prior therapy

    Step Therapy Requirements (Summary Table)

    Drug / GroupStep requirement
    Diclofenac Sodium GEL 3%
    Trial of either topical fluorouracil OR topical imiquimod required prior to coverage
    Drug / GroupStep requirement
    Listed antidepressant products (e.g., Exxua Titration Pack, Fetzima, Fetzima Titration Pack)
    Trial of two generics from the formulary list (bupropion; mirtazapine; citalopram tablet or solution; desvenlafaxine succinate ER; duloxetine; escitalopram; fluoxetine; fluvoxamine; paroxetine; sertraline; venlafaxine HCl) required prior to coverage; approve continuation of prior therapy
    Drug / GroupStep requirement
    Atypical antipsychotic products (e.g., Fanapt, Fanapt titration packs, Lybalvi, Secuado)
    Trial of two oral generic formulary atypical antipsychotics (asenapine; aripiprazole; olanzapine; paliperidone; quetiapine; risperidone; ziprasidone) required prior to coverage; approve continuation of prior therapy
    Drug / GroupStep requirement
    Invega Hafyera (new starts)
    Trial of Invega Sustenna OR Invega Trinza required for new starts prior to coverage; continuation of prior therapy approved
    Drug / GroupStep requirement
    Relistor
    Trial of one of the following required prior to coverage: lubiprostone; Constulose; Enulose; Generlac; OR lactulose
    Drug / GroupStep requirement
    Rytary
    Trial of one generic carbidopa/levodopa containing formulation required prior to coverage
    Drug / GroupStep requirement / notes
    Branded products with step requirements (examples: Rytary; Zonisade)
    Trial of specified generic alternatives required prior to coverage. For Rytary: trial of one generic carbidopa/levodopa formulation. For Zonisade (new starts only): trial of generic zonisamide capsule required; continuation of prior therapy is approved.

    Provider Actions, Documentation & Prior Authorization

    Prior Authorization

    Diclofenac Prior Authorization: prior trial required

    Require prior authorization for Diclofenac Sodium GEL 3% and document that the member has tried either topical fluorouracil or topical imiquimod before approval.

    • Prior trial of either topical fluorouracil OR topical imiquimod is required.
    Prior Authorization

    Antidepressants Prior Authorization: two generic trials required

    Require prior authorization for the listed antidepressant brands and document trials of two different generic formulary antidepressants from the enumerated list; continuation of previously established therapy is permitted.

    • Trial of two generics from: bupropion, mirtazapine, citalopram (tablet or solution), desvenlafaxine succinate ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine hydrochloride.
    • Approve continuation of prior therapy.

    Continuation Therapy Criteria

    inv-41: Antidepressant continuation

    Continuation rule for antidepressants

    Continuation: Approve for continuation of prior therapyprior therapy documented

    from chunk 7

    inv-42: Atypical antipsychotic continuation

    Continuation rule for atypical antipsychotics

    Continuation: Approve for continuation of prior therapyprior therapy documented

    from chunk 10

    inv-43: Invega Hafyera continuation

    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyACTINIC KERATOSIS - SCORE (Step Therapy Criteria)
    Policy CodePolicy N/A
    Change TypeAdministrative — no material changes
    Effective DateMar 1, 2026
    Last ReviewFeb 2, 2026
    Next Review DateFeb 2, 2026
    Key ActionDocument and confirm prior trials of specified generic alternatives before requesting approval (e.g., trial of topical fluorouracil or imiquimod for diclofenac; two generic antidepressants for listed antidepressants).
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy Criteria (Step Therapy)Step Therapy Requirements (Summary Table)Provider Actions, Documentation & Prior AuthorizationContinuation Therapy Criteria

    inv-40: Initial Therapy

    Initial therapy requirements (step therapy)

    Rytary initial: Trial of one generic carbidopa/levodopa containing formulation required

    chunk 19

    Zonisade initial: Trial of generic zonisamide capsule required for new starts

    chunk 22; step applies to new starts only; continuation approved

    Prior Authorization

    Atypical Antipsychotics Prior Authorization: two generic trials required

    Require prior authorization for Fanapt and related atypical antipsychotic products and document trials of two oral generic formulary atypical antipsychotics from the specified list; continuation of prior therapy is allowed.

    • Trial of two of: asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone.
    • Approve continuation of prior therapy.
    Prior Authorization

    Invega Hafyera Prior Authorization: new-start trial required

    Require prior authorization for new starts of Invega Hafyera and document a trial of Invega Sustenna or Invega Trinza; members already on Invega Hafyera may continue therapy without meeting the new-start step.

    • For new starts, trial of Invega Sustenna OR Invega Trinza is required.
    • Approve continuation of prior therapy.
    Prior Authorization

    Relistor Prior Authorization: trial of listed agents required

    Require prior authorization for Relistor and document that the member has tried one of the listed bowel agents prior to approval.

    • Trial of lubiprostone, Constulose, Enulose, Generlac, OR lactulose is required.
    Prior Authorization

    Rytary Prior Authorization: generic carbidopa/levodopa trial required

    Require prior authorization for Rytary and document a prior trial of one generic carbidopa/levodopa formulation before approving Rytary.

    • Trial of one generic carbidopa/levodopa containing formulation is required.
    Step Therapy

    Zonisade Step Requirement: generic zonisamide trial for new starts

    For new starts of Zonisade, require a trial of a generic zonisamide capsule; members already receiving Zonisade may continue without meeting the step requirement.

    • Trial of generic zonisamide capsule is required for new starts.
    • Approve continuation of prior therapy.
    Step Therapy

    Diclofenac Step: topical agent trial required

    Restate the step requirement for Diclofenac Sodium GEL 3%: prior trial of topical fluorouracil or topical imiquimod is required before coverage.

    • Trial of either topical fluorouracil OR topical imiquimod required prior to Diclofenac Sodium GEL 3%.
    Step Therapy

    Antidepressant Step: two generic trials required

    Restate that for the listed antidepressant brands a step requiring trials of two generics from the enumerated formulary list must be documented; continuation of existing therapy is permitted.

    • Trial of two generics from the enumerated antidepressant list is required.
    • Approve continuation of prior therapy.
    Step Therapy

    Atypical Antipsychotic Step: two generic trials required

    Restate that Fanapt and related atypical antipsychotic products require trials of two oral generic formulary atypical antipsychotics from the specified list before approval; continuation of prior therapy is allowed.

    • Trial of two of: asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone.
    • Approve continuation of prior therapy.
    Step Therapy

    Invega Hafyera Step: Sustenna or Trinza trial for new starts

    Restate the Invega Hafyera new-start step: trial of Invega Sustenna or Invega Trinza is required for new initiations; members already on therapy may continue.

    • For new starts, trial of Invega Sustenna OR Invega Trinza required.
    • Approve continuation of prior therapy.
    Step Therapy

    Relistor Step: trial of listed constipation agents required

    Restate that Relistor requires a prior trial of one of the listed constipation agents (lubiprostone, Constulose, Enulose, Generlac, or lactulose) before approval.

    • Trial of lubiprostone, Constulose, Enulose, Generlac, OR lactulose required.
    Step Therapy

    Rytary Step: generic carbidopa/levodopa trial required

    Restate that Rytary requires a prior trial of a generic carbidopa/levodopa formulation before Rytary will be covered.

    • Trial of one generic carbidopa/levodopa containing formulation required prior to Rytary.
    Note

    Generic Alternatives Step Summary

    Summarize that step therapy requires documented trials of the specified generic alternatives prior to coverage of the branded products; this applies to new starts (Zonisade step applies to new starts only) while continuation of prior therapy is approved.

    • Trial of specified generic alternatives is required prior to branded product coverage.
    • Zonisade step applies to new starts only; continuation allowed for existing therapy.
    Documentation Required

    Diclofenac Documentation: prior trial must be recorded

    Document prior trial of either topical fluorouracil or topical imiquimod when requesting Diclofenac Sodium GEL 3%.

    • Include evidence of trial with either topical fluorouracil OR topical imiquimod in the prior authorization documentation.
    Documentation Required

    Antidepressant Documentation: record two generic trials

    Document trials of two generic formulary antidepressants from the enumerated list when requesting coverage for the listed antidepressant brands; continuation of previously established therapy should be documented for approval.

    • List the two generic agents tried from: bupropion, mirtazapine, citalopram (tablet or solution), desvenlafaxine succinate ER, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine hydrochloride.
    • Document prior therapy for continuation approvals.
    Documentation Required

    Atypical Antipsychotic Documentation: record two generic trials

    Document trials of two oral generic formulary atypical antipsychotics from the specified list when requesting coverage for Fanapt and related products; document prior therapy for continuation approvals.

    • Record trials of two of: asenapine, aripiprazole, olanzapine, paliperidone, quetiapine, risperidone, ziprasidone.
    • Document prior therapy for continuation.
    Documentation Required

    Invega Hafyera Documentation: new-start trial required

    For new starts of Invega Hafyera, document a trial of Invega Sustenna or Invega Trinza in the prior authorization request; members already on Invega Hafyera may continue therapy with documentation of prior use.

    • Document trial of Invega Sustenna OR Invega Trinza for new starts.
    • Document prior therapy for continuation approvals.
    Documentation Required

    Relistor Documentation: record trial of listed agents

    Document prior trial of one of the listed constipation agents (lubiprostone, Constulose, Enulose, Generlac, or lactulose) before requesting Relistor.

    • Include evidence of trial with one of the listed agents in the prior authorization documentation.
    Documentation Required

    Rytary Documentation: generic carbidopa/levodopa trial must be shown

    Document a prior trial of one generic carbidopa/levodopa formulation before approving Rytary; include the specific generic formulation used.

    • Document which generic carbidopa/levodopa containing formulation was trialed.
    Documentation Required

    Misc Documentation: Rytary and Zonisade trials must be recorded

    Document prior trial of one generic carbidopa/levodopa formulation for Rytary requests and document trial of a generic zonisamide capsule for new starts of Zonisade; note that Zonisade step applies to new starts only and continuation of prior therapy is approved.

    • Rytary: document one generic carbidopa/levodopa formulation trialed.
    • Zonisade (new starts): document trial of a generic zonisamide capsule; document prior therapy for continuation.
    Denial Risk

    Diclofenac Denial Risk: missing topical trial

    Failure to document a required trial of topical fluorouracil or topical imiquimod may result in denial of coverage for Diclofenac Sodium GEL 3%.

    • Denial risk if documentation of the required topical trial is not provided.
    Denial Risk

    Antidepressant Denial Risk: missing two generic trials

    Failure to document trials of two generic formulary antidepressants from the enumerated list may result in denial for the listed antidepressant products.

    • Denial risk if two generic trials are not documented.
    Denial Risk

    Atypical Antipsychotic Denial Risk: missing two generic trials

    Failure to document trials of two listed generic atypical antipsychotics may result in denial for Fanapt and related products.

    • Denial risk if two generic atypical antipsychotic trials are not documented.
    Denial Risk

    Invega Hafyera Denial Risk: missing required Sustenna/Trinza trial

    For Invega Hafyera new starts, lack of documentation showing a trial of Invega Sustenna or Invega Trinza may lead to denial.

    • Denial risk if the required Sustenna or Trinza trial is not documented for new starts.
    Denial Risk

    Relistor Denial Risk: missing trial of listed agents

    Absence of documentation showing prior trial of lubiprostone, Constulose, Enulose, Generlac, or lactulose may lead to denial of Relistor requests.

    • Denial risk if prior trial of one listed constipation agent is not documented.
    Denial Risk

    Rytary Denial Risk: missing generic carbidopa/levodopa trial

    Absence of documentation showing a required trial of one generic carbidopa/levodopa formulation may lead to denial for Rytary.

    • Denial risk if the generic carbidopa/levodopa trial is not documented.
    Denial Risk

    Misc Denial Risks: missing required generic trials

    Failure to document required trials of specified generics (one generic carbidopa/levodopa for Rytary; generic zonisamide capsule for Zonisade new starts) may trigger a denial.

    • Denial risk for Rytary if generic carbidopa/levodopa trial not shown.
    • Denial risk for Zonisade new starts if generic zonisamide capsule trial not shown.

    Continuation rule for Invega Hafyera

    Continuation: Approve for continuation of prior therapyprior therapy documented

    from chunk 13

    inv-44: Continuation Therapy

    Continuation allowed

    Zonisade continuation: Approve continuation of prior therapy (step applies to new starts only)

    chunk 22